11 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2041. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Jan 2041
Next term end
8
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2041 · High confidence
Also notable
Ends Jan 2041 · High confidence
Also notable
Ends Jan 2041 · High confidence
Methods of Treating Wandering in Lewy Body Dementia
US 11,642,352
The most cited patent in this portfolio, cited by 3 later US patents, top 25% of utility patents granted in 2023 in our data. Protection runs to 2041. A terminal disclaimer caps this term to an earlier patent's.
Methods of Treating Cortical Dementia Associated Wandering
US 11,666,583
The newest of the three, granted 2023. It anchors the portfolio to 2041, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease
US 11,771,704
The newest of the three, granted 2023. It anchors the portfolio to 2041, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 6, 2026The maintenance fee for Methods of Treating Cortical Dementia Associated Wandering (US 11,666,583) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
- 2 fees due Apr 3 to 10, 2027 · next Apr 3
- 1 fee due Jul 9, 2027The maintenance fee for Methods of Treating Agitation and Other Dementia-Associated Behavioral Symptoms (US 11,865,119) comes due Jul 9, 2027. Unpaid by Jan 10, 2028, it lapses early.
- 1 fee due Oct 2, 2027The maintenance fee for Oral Formulations of Fasudil with Ion Exchange Resin (US 11,944,633) comes due Oct 2, 2027. Unpaid by Apr 3, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 8 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Oral Formulations of Fasudil with Ion Exchange Resin | 2 in force | to Feb 2043 |
| Method of Treating Amyotrophic Lateral Sclerosis | 2 in force | to Jan 2042 |
| Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease | 2 in force | to Jan 2041 |
| Methods of Treating Agitation and Other Dementia-Associated Behavioral Symptoms | 1 in force | to Nov 2042 |
| Methods of Treating Wandering in Lewy Body Dementia | 1 in force | to Jan 2041 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,311,553 | Methods of Treating 4-Repeat Tauopathies In force · High confidence | In force | High confidence | |
| US 11,642,352 | Methods of Treating Wandering in Lewy Body Dementia In force · High confidence | In force | High confidence | |
| US 11,666,583 | Methods of Treating Cortical Dementia Associated Wandering In force · High confidence | In force | High confidence | |
| US 11,771,704 | Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease In force · High confidence | In force | High confidence | |
| US 12,329,761 | Methods of Using Rho Kinase Inhibitors to Treat Alzheimer's Disease In force · High confidence | In force | High confidence | |
| US 12,290,522 | Method of Treating Amyotrophic Lateral Sclerosis In force · Medium confidence | In force | Medium confidence | |
| US 11,779,588 | Method of Treating Amyotrophic Lateral Sclerosis In force · High confidence | In force | High confidence | |
| US 11,865,119 | Methods of Treating Agitation and Other Dementia-Associated Behavioral Symptoms In force · High confidence | In force | High confidence | |
| US 11,944,633 | Oral Formulations of Fasudil with Ion Exchange Resin In force · High confidence | In force | High confidence | |
| US 12,115,167 | Oral Formulations of Fasudil with Ion Exchange Resin In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 11: 22 applications pending · 11 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.